Supporting our hypothesis that combination treatment targeting HER2 with anti-androgen may be an effective treatment for CRPC, our results showed that adding Lapatinib treatment to ENZ significantly reduced tumor volume compared to animals treated with ENZ alone (Fig. 5F). This evidence concerns the gene ERBB2 and neoplasm.